All In Biotech

Drug Trial Radar · NCT05986240

Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML

A Phase I Study Investigating the Safety & Efficacy of Danvatirsen as Monotherapy Followed by Combination With Venetoclax in Patients With Relapsed/Refractory MDS & AML

Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

38

Planned (sponsor's estimate)

Start

May 8, 2024

Primary completion

Jun 2027

Study completion Mar 2030

Sponsor

Lead sponsor
Montefiore Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
M.D. Anderson Cancer Center; Flamingo Therapeutics NV; FDA Office of Orphan Products Development
First posted
Aug 14, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase 1 study investigating the safety and efficacy of Danvatirsen as a monotherapy followed by combination with Venetoclax in patients with relapsed/refractory myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML). Funding Source: FDA OOPD

Conditions

  • AML/MDS
  • Acute Myeloid Leukemia
  • Myelodysplastic Syndromes

Interventions

  • DanvatirsenDrug

    Danvatirsen (AZD9150) is a selective, high-affinity, antisense oligonucleotide inhibitor of signal transducer and activator of transcription 3 (or STAT3).

  • Danvatirsen + VenetoclaxCombination product

    Danvatirsen (AZD9150) is a selective, high-affinity, antisense oligonucleotide inhibitor of signal transducer and activator of transcription 3 (or STAT3). Venetoclax: Commercially available. Venetoclax is a potent, selective small molecule inhibitor of BCL-2, an anti-apoptotic protein found on some types of cancer cells.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Response to Therapy as determined by Overall Response RateTime frame: From 21 days after initiation of study treatment to within 14 days following treatment discontinuation; up to 14 weeks total

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Montefiore Medical Center

    The Bronx, New York · Recruiting

  • M.D. Anderson Cancer Center, Department of Leukemia

    Houston, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.